For media enquiries please contact:

Latest Press Release

Evive Biotech and Dr. Xiao Qiang Yan Form Joint Venture to Further Develop Bi-specific Antibody Platform ITab

Evive Biotech Announces First Patient Dosed in Phase 2 Study to Evaluate the Efficacy and Safety of F-652 in Patients with Moderate to Severe COVID-19

Mucosal Immunology Article Details IL-22’s Critical Role in Maturation of Certain Epithelial Cells

Evive Biotech Meets Primary and Secondary Endpoints in Global Phase III Clinical Trial for Their Novel Chemotherapy-induced Neutropenia Treatment

Evive Successfully Concludes China Phase III Clinical Trial of F-627 for Chemotherapy-induced Neutropenia

Evive Receives Orphan-Drug Designation from the U.S. FDA for F-652 for the Treatment of Acute Graft vs Host Disease

Evive Announces Initiation of a Phase I Trial of A-319 to Treat Patients with B Cell Malignancies

Evive Receives Investigative New Drug (IND) Approval from China SFDA for A-319 to Treat Patients with B Cell Malignancies

Evive’s F-652 Shows Positive Results in “An Open Label, Cohort Dose Escalation Study to Assess the Safety and Efficacy in Patients with Alcoholic Hepatitis”

Media Library